Sublingual Eliglustat Composition to Bypass First-Pass Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral formulations of eliglustat for treating Gaucher disease type 1 suffer from low bioavailability due to significant first-pass metabolism, necessitating complex dosing regimens based on CYP2D6 genotype and limited efficacy.
Innovation Solution
A transmucosal pharmaceutical composition, particularly sublingual, that circumvents hepatic metabolism, enhancing bioavailability and allowing for reduced dosing by directly delivering eliglustat through mucosal linings, thereby improving pharmacokinetic parameters like Cmax, AUC(0-t), and AUC0-inf.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration of eliglustat is used, then the treatment can be administered conveniently, but the bioavailability is low due to first-pass metabolism
Solution Approach 1:
The patent uses a transmucosal delivery system (sublingual or buccal) as an intermediary route between oral administration and direct systemic delivery. This mediator allows the drug to bypass hepatic first-pass metabolism while maintaining ease of administration through the oral cavity, achieving both convenience and high bioavailability
2Device complexity
If standard oral dosage is used, then the treatment regimen is simple, but the dosing complexity increases due to CYP2D6 genotype requirements
Solution Approach 1:
The patent extracts the problematic CYP2D6 metabolic pathway from the treatment equation by using transmucosal delivery. This removes the need for genotype-based dosing adjustments while maintaining treatment efficacy, as the drug bypasses hepatic metabolism and enters systemic circulation directly through the mucosal lining
3Reliability
If higher oral doses are used to compensate for low bioavailability, then the treatment coverage is improved, but the side effects increase
Solution Approach 1:
The patent changes the delivery parameter from oral to transmucosal route, which fundamentally alters the pharmacokinetic profile. This parameter change enables achieving the same treatment coverage with lower doses since the drug bypasses first-pass metabolism, thereby reducing side effects while maintaining efficacy
Data Source
AI summary
The present invention relates to a pharmaceutical composition comprising glucosylceramide synthase inhibitor and a one or more pharmaceutically acceptable excipients. The present invention specifically relates to a sublingual pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof and a one or more pharmaceutically acceptable excipients. Moreover, the present invention further relates to a pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof which is used in the treatment of individual with lysozymal storage diseases selected from the group consisting of, Gaucher disease, Sphingolipidoses, Farber disease, Krabbe disease, Fabry disease, Schindler disease, Tay-Sachs disease and Niemann-Pick disease.